COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc develops novel medicines for the treatment of human viral diseases. It focuses on the development and commercialization of broad-spectrum antiviral drug candidates that transforms the treatment and prophylaxis of diseases in humans.

As of 10/15/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/03/2013
Outstanding shares:  97,468,755
Average volume:  563,841
Market cap:   $92,712,280
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    19188J300
ISIN:        US19188J3005
Valuation   (See tab for details)
PE ratio:   -13.28
PB ratio:   1.08
PS ratio:   61.44
Return on equity:   -12.65%
Net income %:   -710.54%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy